88.94
3.03 (3.53%)
| Previous Close | 85.91 |
| Open | 86.32 |
| Volume | 775,157 |
| Avg. Volume (3M) | 907,167 |
| Market Cap | 4,812,214,272 |
| Price / Sales | 23.36 |
| Price / Book | 20.41 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2024 |
| Profit Margin | -50.07% |
| Operating Margin (TTM) | -38.42% |
| Diluted EPS (TTM) | -1.95 |
| Quarterly Revenue Growth (YOY) | 66.30% |
| Total Debt/Equity (MRQ) | 34.26% |
| Current Ratio (MRQ) | 6.02 |
| Operating Cash Flow (TTM) | -91.61 M |
| Levered Free Cash Flow (TTM) | -82.85 M |
| Return on Assets (TTM) | -16.73% |
| Return on Equity (TTM) | -37.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | PROCEPT BioRobotics Corporation | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.5 |
| Average | 0.20 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.65% |
| % Held by Institutions | 86.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Truist Securities, 18.06%) | Buy |
| Median | 95.00 (6.81%) | |
| Low | 75.00 (Piper Sandler, -15.67%) | Buy |
| Average | 93.60 (5.24%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 83.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 14 Nov 2024 | 95.00 (6.81%) | Hold | 85.91 |
| Truist Securities | 30 Oct 2024 | 105.00 (18.06%) | Buy | 93.03 |
| 03 Sep 2024 | 95.00 (6.81%) | Buy | 75.06 | |
| Piper Sandler | 08 Oct 2024 | 75.00 (-15.67%) | Buy | 74.00 |
| TD Cowen | 16 Sep 2024 | 99.00 (11.31%) | Buy | 81.99 |
| B of A Securities | 22 Aug 2024 | 94.00 (5.69%) | Buy | 80.27 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DESAI ANTAL ROHIT | - | 96.23 | -34,000 | -3,271,820 |
| ZADNO REZA | - | 92.25 | -26,420 | -2,437,245 |
| Aggregate Net Quantity | -60,420 | |||
| Aggregate Net Value ($) | -5,709,065 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 94.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ZADNO REZA | Officer | 13 Nov 2024 | Automatic sell (-) | 26,420 | 92.25 | 2,437,245 |
| DESAI ANTAL ROHIT | Director | 07 Nov 2024 | Automatic sell (-) | 34,000 | 96.23 | 3,271,820 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |